CTXR Citius Pharmaceuticals, Inc.
Price Chart
Executive Summary
Citius Pharmaceuticals reported Q2 fiscal 2026 revenue of $1.7M (vs $0 a year ago) from LYMPHIR sales, but net loss widened to $21.2M ($0.95/sh) from $10.9M ($1.27/sh) in the prior-year quarter, driven by a $19.7M one-time CMO cancellation charge. Cash dropped to $4.6M, and the company raised $5M in a direct offering in April 2026, while Citius Oncology secured up to $36.5M in debt/equity. Despite commercial progress, the growing losses and cash burn signal ongoing capital needs and dilution risk.
Key Financial Metrics
Actionable Insight
Monitor the LYMPHIR revenue trajectory over the next 1-2 quarters for signs of sustainable growth; the company's limited cash runway (through Nov 2026) and reliance on additional financing create near-term dilution risk. The subsequent financing at Citius Oncology is positive but does not offset the core cash burn.
Key Facts
- Q2 FY2026 net product revenue of $1.7M, down from $3.9M in Q1 (initial launch stocking orders)
- Net loss applicable to common stockholders of $21.2M vs $10.9M in Q2 2025
- G&A expenses surged to $26.4M from $4.8M, including a $19.7M one-time CMO contract cancellation charge
- Cash and cash equivalents fell to $4.6M at March 31, 2026, from $7.7M at December 31, 2025
- Subsequent to quarter end: $5M registered direct offering at Citius Pharma; Citius Oncology secured up to $36.5M debt/equity
- Company expects sufficient funds to continue operations only through November 2026
Financial Impact
Net loss doubled YoY to $21.2M; cash burn of ~$14.3M in operating cash flow for H1 FY2026
Risk Factors
- Dilution from recent and potential future equity offerings
- Cash runway only through November 2026; going-concern risk if revenue does not ramp
- Commercial execution risk for LYMPHIR; QoQ revenue decline from launch quarter
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-057876 |
| Document: ea0291037-8k_citius.htm | 0001213900-26-057876 |
| Document: 0001213900-26-057876-index-headers.html | 0001213900-26-057876 |
| Document: 0001213900-26-057876-index.html | 0001213900-26-057876 |
| Document: 0001213900-26-057876.txt | 0001213900-26-057876 |
| 8-K Data (Synthetic) | 0001213900-26-057876 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
12d ago
|
EFFECT
| $0.5800 $0.5900 | ▼ −1.72% | ▼ −1.33% | $0.5400 (+6.90%) |
|
Jun 1, 2026
13d ago
|
8-K
| $0.6030 $0.5800 | ▼ −3.81% | ▼ −3.09% | $0.5400 (−10.45%) |
|
May 22, 2026
23d ago
|
S-3
| $0.6970 $0.6900 | ▲ +1.00% | ▲ +1.02% | $0.5400 (+22.53%) |
|
May 15, 2026
4w ago
|
8-K
| $0.5270 $0.5540 | ▼ −5.12% | ▼ −5.77% | $0.5400 (−2.47%) |
|
Apr 24, 2026
7w ago
|
8-K
| $0.6910 $0.6500 | ▲ +5.93% | ▲ +5.45% | $0.5400 (+21.85%) |
|
Apr 24, 2026
7w ago
|
424B5
| $0.7700 $0.6910 | ▲ +10.26% | ▲ +10.42% | $0.5400 (+29.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access